Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Edmond de Rothschild Investment Partners. (4/18/13). "Press Release: Edmond de Rothschild Investment Partners Co-leads €15 Million Series A Financing of Allecra Therapeutics with Its New Fund BioDiscovery 4". Paris.

Region Region Lörrach
  Country Germany
Organisations Organisation Allecra Therapeutics GmbH
  Group Allecra Therapeutics (Group)
  Organisation 2 Edmond de Rothschild Investment Partners (EdRIP)
  Today Andera Partners (FR)
  Group Andera Partners (FR)
Products Product antibiotic
  Product 2 BioDiscovery 4 Fund (Edmond de Rothschild)
Index term Index term Allecra Therapeutics–SEVERAL: investment, 201304 financing round Series A €15m co-led by EdRIP + Forbion
Persons Person Benedict, Nicholas (Allecra Therapeutics 201304 CEO + Co-Founder)
  Person 2 Litzka, Olivier (LCF Rothschild 2006–200911– Partner EdRIP before 3i Venture Healthcare)
     


Edmond de Rothschild Investment Partners announces the first investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series A financing round of Allecra Therapeutics, which it co-leads with Forbion Capital Partners. EMBL Ventures is also part of the syndicate.

Allecra was formed in 2013 in France and Germany, as a strategic partnership between Orchid Chemicals & Pharmaceuticals Limited (Chennai, India), the founders - including Allecra's CEO Nicholas Benedict - and the two lead investors. This Series A financing of €15 million euros will support early clinical development of two new antibiotic treatments designed to combat multi drugresistant gram-negative bacteria.

Olivier Litzka, Partner at Edmond de Rothschild Investment Partners and Board Director at Allecra commented: "Allecra's strategic partnership with Orchid is an innovative collaboration bringing together Allecra's strong development capability with Orchid's track record in antibiotic research and manufacturing. Allecra is supported by a Scientific Advisory Board consisting of world-renowned experts and Allecra's Board of Directors comprises key appointments of entrepreneurs and industrialists with records of success in this area."

Olivier Litzka also added: "We are glad to see Allecra become the first investment of our fund Biodiscovery 4. After our successful experience in the anti-infectives space through the investment of the BioDiscovery funds in Novexel, we are convinced that Allecra has all the major ingredients for success."

Nicholas Benedict, Co-Founder and CEO of Allecra added: "The formation of Allecra comes at a time when governments, non-governmental agencies and the medical community are crying out for urgent and decisive action to tackle "the epidemic of antibiotic resistance. Our mission at Allecra is to develop new treatments which overcome selected bacterial resistance and which can be used to treat patients whose infections may otherwise have disastrous consequences."


About Edmond de Rothschild Investment Partners

Paris-based Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group which is specialized in asset management and private banking (EUR 130bn under management, 2,900 employees and 30 offices throughout the world). Founded in 1953, the Group has been chaired since 1997 by the founder's son, Baron Benjamin de Rothschild.

Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It has currently close to €1 billion under management which is being invested primarily as life sciences venture capital and growth capital.

Its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The team has €355 million under management through its Biodiscovery franchise.

BioDiscovery Funds, including BioDiscovery 4, are venture capital funds registered via the fast-track procedure. These funds are not authorized by the Autorité des marchés financiers and may adopt special investment rules. BioDiscovery 4, a Capital Venture Funds registered via the fast-track procedure, invests mainly in private companies, which involves specific risks such as a risk of capital loss, a discretionary management risk and a liquidity risk.

For more information please visit: www.edrip.fr.

Press contacts:

Edmond de Rothschild Investment Partners
Laetitia Guillot-Tantay
00 33 [1] 40 17 89 26 00
laetitia.guillot-tantay@lcfr.fr

Citigate
Daphné Claude / Laura Barkatz
33 [1] 53 32 78 90 / 00 33 [1] 53 32 84 73
daphne.claude@citigate.fr
laura.barkatz@citigate.fr

   
Record changed: 2017-04-02

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Allecra Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px




» top